HEAD-TO-HEAD COMPARISON OF TLL-018 AND TOFACITINIB IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS: INTERIM RESULTS FROM A PHASE IIA STUDY

被引：2
|
作者：
Zeng, X. [1 ]
Wu, C. [1 ]
Hu, J. [2 ]
Liu, S. [3 ]
Jiang, Z. [4 ]
Li, J. [5 ]
Wang, X. [6 ]
Liu, J. [7 ]
Liang, C. [8 ]
Yang, G. [8 ]
机构：
[1] Peking Union Med Coll Hosp, Dept Rheumatol & Clin Immunol, Beijing, Peoples R China
[2] Pingxiang Peoples Hosp, Dept Rheumatol & Clin Immunol, Pingxiang, Peoples R China
[3] Zhengzhou Univ, Dept Rheumatol & Clin Immunol, Affiliated Hosp 1, Zhengzhou, Peoples R China
[4] Jilin Univ, Dept Rheumatol & Clin Immunol, Affiliated Hosp 1, Changchun, Peoples R China
[5] Zhuzhou Cent Hosp, Dept Rheumatol & Clin Immunol, Zhuzhou, Peoples R China
[6] Shanxi Med Univ, Dept Rheumatol & Clin Immunol, Hosp 2, Taiyuan, Shanxi, Peoples R China
[7] Jiujiang 1 Peoples Hosp, Dept Rheumatol & Clin Immunol, Jiujiang, Peoples R China
[8] Highlightll Pharma, Hangzhou, Peoples R China
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2023年 / 82卷
关键词：
Rheumatoid arthritis; non biologic treatment and small molecules;
D O I：
10.1136/annrheumdis-2023-eular.7058
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
LB0001
引用
收藏
页码：200 / 200
页数：1
相关论文
共 50 条
  • [21] Efficacy and safety of pateclizumab (anti-lymphotoxin-α) compared to adalimumab in rheumatoid arthritis: a head-to-head phase 2 randomized controlled study (The ALTARA Study)
    Kennedy, William P.
    Simon, J. Abraham
    Offutt, Carolyn
    Horn, Priscilla
    Herman, Ann
    Townsend, Michael J.
    Tang, Meina T.
    Grogan, Jane L.
    Hsieh, Frank
    Davis, John C., Jr.
    [J]. ARTHRITIS RESEARCH & THERAPY, 2014, 16 (05)
  • [22] Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study (vol 388, pg 2763, 2016)
    Smolen, J. S.
    Burmester, G-R
    Combeet, B.
    [J]. LANCET, 2017, 389 (10068): : E2 - E2
  • [23] Efficacy and safety of pateclizumab (anti-lymphotoxin-α) compared to adalimumab in rheumatoid arthritis: a head-to-head phase 2 randomized controlled study (The ALTARA Study)
    William P Kennedy
    J Abraham Simon
    Carolyn Offutt
    Priscilla Horn
    Ann Herman
    Michael J Townsend
    Meina T Tang
    Jane L Grogan
    Frank Hsieh
    John C Davis
    [J]. Arthritis Research & Therapy, 16
  • [24] Effects of once-monthly minodronate versus risedronate in osteoporosis patients with rheumatoid arthritis: a 12-month randomized head-to-head comparison
    K. Kumagai
    K. Harigane
    Y. Kusayama
    T. Tezuka
    H. Choe
    Y. Inaba
    T. Saito
    [J]. Osteoporosis International, 2018, 29 : 1637 - 1642
  • [25] Natalizumab versus fingolimod for patients with active relapsing-remitting multiple sclerosis: results from REVEAL, a prospective, randomised head-to-head study
    Butzkueven, Helmut
    Licata, Stephanie
    Jeffery, Douglas
    Arnold, Douglas L.
    Filippi, Massimo
    Geurts, Jeroen J. G.
    Santra, Sourav
    Campbell, Nolan
    Ho, Pei-Ran
    [J]. BMJ OPEN, 2020, 10 (10):
  • [26] Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial
    Schiff, Michael
    Weinblatt, Michael E.
    Valente, Robert
    van der Heijde, Desiree
    Citera, Gustavo
    Elegbe, Ayanbola
    Maldonado, Michael
    Fleischmann, Roy
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 (01) : 86 - 94
  • [27] Changes in serum creatinine in patients with active rheumatoid arthritis treated with tofacitinib: results from clinical trials
    John D Isaacs
    Andrea Zuckerman
    Sriram Krishnaswami
    Chudy Nduaka
    Shuping Lan
    Matthew M Hutmacher
    Mary G Boy
    Ken Kowalski
    Sujatha Menon
    Richard Riese
    [J]. Arthritis Research & Therapy, 16
  • [28] Changes in serum creatinine in patients with active rheumatoid arthritis treated with tofacitinib: results from clinical trials
    Isaacs, John D.
    Zuckerman, Andrea
    Krishnaswami, Sriram
    Nduaka, Chudy
    Lan, Shuping
    Hutmacher, Matthew M.
    Boy, Mary G.
    Kowalski, Ken
    Menon, Sujatha
    Riese, Richard
    [J]. ARTHRITIS RESEARCH & THERAPY, 2014, 16 (04)
  • [29] DEVELOPMENT OF ABATACEPT- AND ADALIMUMAB-SPECIFIC PREDICTIVE MODELS OF RESPONSE TO THERAPY IN RHEUMATOID ARTHRITIS USING DATA FROM A HEAD-TO-HEAD STUDY
    Bandyopadhyay, Somnath
    Maldonado, Michael A.
    Ammar, Ron
    Schiff, Michael
    Weinblatt, Michael
    Fleischmann, Roy
    Connolly, Sean E.
    [J]. RHEUMATOLOGY, 2018, 57
  • [30] Head-to-head comparison of the safety of tocilizumab and tumor necrosis factor inhibitors in rheumatoid arthritis patients (RA) in clinical practice: results from the registry of Japanese RA patients on biologics for long-term safety (REAL) registry
    Ryoko Sakai
    Soo-Kyung Cho
    Toshihiro Nanki
    Kaori Watanabe
    Hayato Yamazaki
    Michi Tanaka
    Ryuji Koike
    Yoshiya Tanaka
    Kazuyoshi Saito
    Shintaro Hirata
    Koichi Amano
    Hayato Nagasawa
    Takayuki Sumida
    Taichi Hayashi
    Takahiko Sugihara
    Hiroaki Dobashi
    Shinsuke Yasuda
    Tetsuji Sawada
    Kazuhiko Ezawa
    Atsuhisa Ueda
    Takao Fujii
    Kiyoshi Migita
    Nobuyuki Miyasaka
    Masayoshi Harigai
    [J]. Arthritis Research & Therapy, 17
12345